Back to results
US 2022/0010012 A1Published application
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
AssigneeNovo Nordisk A/S
InventorsAnette HENRIKSEN, Kristian KJAERGAARD, Vibeke Westphal STENNICKE, Charlotte WIBERG
Life of this patent
Estimating the term…
Abstract
Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Claims12
-16. (canceled)
An antibody or fragment thereof that is capable of binding to and blocking TREM-1, wherein:
- the antibody or fragment thereof has a viscosity of less than 5 cP at a concentration of 80 mg/mL;
- and
- the antibody or fragment thereof comprises a variant of SEQ ID NO:
- 3 wherein at least one or both of E27 and E97 of the CDR1 and CDR3 regions of SEQ ID NO:
- 3 is substituted with an amino acid residue selected from the group consisting of glycine, alanine, serine, asparagine, glutamine, threonine, cysteine, and tyrosine.
2 more elements
Dependencies are inferred from the claim text.